Edited Transcript of CALA earnings conference call or presentation 7-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/04 20:22
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 06/02 12:00
Calithera Biosciences To Present Telaglenastat KEAPSAKE Trial In Progress Poster At ASCO
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today
Benzinga · 05/29 12:37
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting
The KEAPSAKE study (NCT04265534) will explore telaglenastat versus placebo in combination with a standard-of-care regimen of immunotherapy and chemotherapy as first-line treatment for patients with non-small cell lung cancers (NSCLC) with KEAP1/NRF2 mutations.
GlobeNewswire · 05/29 12:00
Calithera to Present at the Jefferies Virtual Healthcare Conference
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commi
GlobeNewswire · 05/27 11:01
Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year?
Zacks · 05/18 16:30
Is Calithera Biosciences (CALA) Stock a Solid Choice Right Now?